[Microbial secondary metabolites inhibiting oncogene actions].
Uehara
Y
Y
Department of Antibiotics, National Institute of Health, Tokyo.
D000190:Actinomyces / Q000378:metabolism*; D000818:Animals; D016227:Benzoquinones; D002471:Cell Transformation, Neoplastic / Q000187:drug effects / Q000235:genetics*; D047029:Lactams, Macrocyclic; D009857:Oncogenes / Q000187:drug effects*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011809:Quinones / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D017828:Rifabutin / Q000031:analogs & derivatives; D015398:Signal Transduction / Q000187:drug effects; D014407:Tumor Cells, Cultured
D016227:Benzoquinones; D047029:Lactams, Macrocyclic; D011809:Quinones; D017828:Rifabutin; C020754:herbimycin; D011505:Protein-Tyrosine Kinases